• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    10/18/24 12:33:03 PM ET
    $VRDN
    Medical Specialities
    Health Care
    Get the next $VRDN alert in real time by email
    SC 13G/A 1 Viridian_Therapeutics_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    VIRIDIAN THERAPEUTICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    92790C104

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    92790C104 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,205,678

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,379,774

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,379,774.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.2%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    92790C104 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      VIRIDIAN THERAPEUTICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      6200 LOOKOUT ROAD BOULDER CO 80301 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      92790C104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    92790C104 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 2,379,774.00  
      (b) Percent of class: 3.2%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 2,205,678
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 2,379,774
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    92790C104 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $VRDN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRDN

    DatePrice TargetRatingAnalyst
    12/19/2024$37.00 → $27.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024Buy
    TD Cowen
    9/11/2024$30.00 → $38.00Buy
    Needham
    6/11/2024$29.00Outperform
    Wolfe Research
    6/6/2024$23.00Buy
    Goldman
    5/9/2024Buy → Neutral
    Ladenburg Thalmann
    5/9/2024$25.00 → $20.00Buy → Neutral
    B. Riley Securities
    6/14/2023$51.00Outperform
    Credit Suisse
    More analyst ratings

    $VRDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viridian Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Viridian Therapeutics from Overweight to Equal Weight and set a new price target of $27.00 from $37.00 previously

      12/19/24 8:33:15 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on Viridian Therapeutics

      TD Cowen initiated coverage of Viridian Therapeutics with a rating of Buy

      11/25/24 7:56:18 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Needham reiterated coverage on Viridian Therapeutics with a new price target

      Needham reiterated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $38.00 from $30.00 previously

      9/11/24 8:00:48 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Viridian Therapeutics Inc.

      10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      5/6/25 7:55:45 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      5/6/25 7:28:38 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Viridian Therapeutics Inc.

      DEFA14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

      4/25/25 7:57:02 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Financials

    Live finance-specific insights

    See more
    • Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

      - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug

      12/16/24 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

      - THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta

      12/13/24 6:00:00 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

      - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r

      9/10/24 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Beetham Thomas W. bought $117,050 worth of shares (5,000 units at $23.41), increasing direct ownership by 500% to 6,000 units (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/30/24 7:12:50 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • President and CEO Mahoney Stephen F. bought $499,262 worth of shares (21,400 units at $23.33) (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/30/24 7:10:58 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Director Fairmount Funds Management Llc bought $30,000,000 worth of shares (1,600,000 units at $18.75) (SEC Form 4)

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      9/17/24 9:00:13 PM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Leadership Updates

    Live Leadership Updates

    See more

    $VRDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

      - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

      5/6/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

      - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 20

      4/7/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

      - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter o

      2/27/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 5:53:44 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 5:52:18 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

      SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

      11/14/24 4:50:30 PM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ajer Jeffrey Robert

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      4/9/25 4:26:02 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Ajer Jeffrey Robert

      3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      4/9/25 4:19:55 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

      4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

      3/12/25 4:36:26 PM ET
      $VRDN
      Medical Specialities
      Health Care

    $VRDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

      - Breakthrough Therapy Designation request based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response - - Veligrotug met all of its primary and secondary endpoints in the pivotal THRIVE and THRIVE-2 clinical trials in active and chronic TED - - First and only drug candidate in chronic TED to demonstrate statistically significant and clinically meaningful improvement and resolution of diplopia in a global phase 3 clinical trial - - Breakthrough Therapy Designation supports eligibility for Priority Review - - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 wit

      5/7/25 4:15:00 PM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

      - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

      5/6/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care
    • Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company's common stock to 13 new employees (the "Inducement Grants") on May 1, 2025 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of

      5/2/25 7:00:00 AM ET
      $VRDN
      Medical Specialities
      Health Care